Dr.AddMedPHL said:

The dose-response is real but shallow at the top.

I read this differently from Dr.AddMedPHL, on substance rather than tone. The trial means are being read too generously in this thread. STEP populations were selected, supported, and titrated by protocol, and the real-world curves are consistently a few points worse. That difference is not noise, it is what happens when you remove the study infrastructure.

I would rather be corrected than agreed with, if it comes to it.

Adding the numbers, since they settle part of this. Worth knowing that the injection site changes very little. Abdomen, thigh and upper arm are bioequivalent for semaglutide, so a site change is not a plausible explanation for a bad week.

HPLC_Greg said:

The trial means are being read too generously in this thread.

Coming at HPLC_Greg’s question from a different direction. Worth answering the question that was asked rather than the one behind it. The narrow version usually has an answer; the broad version usually does not, and answering the broad one is how a thread stops being useful.

Happy to go further on any of that.

A narrower follow-up, since the general answer is now clear:

Was that from a primary source or from a summary of one?

OP back with an update, since a thread like this is useless without one.

Update. I did go to 2.4mg in the end, and the honest report is that it bought me less than the step before it and cost me two bad weeks. Worth knowing rather than worth repeating.